Sign inCreate account

Report workspace tools

NCT00529373TERMINATEDanonymous

A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium

Sponsor

Source record

Merck Sharp & Dohme LLC

Phase

Source record

Phase III

Modality

AI-normalized

small molecule

Target

AI-normalized

Odanacatib (MK-0822)

Indication / condition

AI-normalized

Postmenopausal Osteoporosis

Intervention

Source record

Odanacatib, Placebo for Odanacatib, Vitamin D3, Calcium carbonate

Source & freshness

Source record

NCT ID

NCT00529373

Original source

ClinicalTrials.gov

Source last updated

Jun 11, 2024

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00529373

Title

A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium

Sponsor

Merck Sharp & Dohme LLC

Status

TERMINATED

Phase

Phase III

Condition raw

Postmenopausal Osteoporosis

Condition normalized

Postmenopausal Osteoporosis

Modality raw

Postmenopausal Osteoporosis

Modality normalized

small molecule

Target raw

Odanacatib (MK-0822)

Target normalized

Odanacatib (MK-0822)

Interventions

Odanacatib, Placebo for Odanacatib, Vitamin D3, Calcium carbonate

Public preview

Source record

This clinical trial assessed the safety and efficacy of Odanacatib in reducing fracture risk among postmenopausal women with osteoporosis. The study involved a total of 16,071 participants, with a randomized, double-blind, placebo-controlled design over a duration of up to 10 years, including extensions.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT00529373

Status

TERMINATED

Phase

Phase III

Sponsor

Merck Sharp & Dohme LLC

Executive brief

Investment-Ready Snapshot

This clinical trial assessed the safety and efficacy of Odanacatib in reducing fracture risk among postmenopausal women with osteoporosis. The study involved a total of 16,071 participants, with a randomized, double-blind, placebo-controlled design over a duration of up to 10 years, including extensions.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJun 11, 2024
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00529373

Indication

Postmenopausal Osteoporosis

Modality

small molecule

Target

Odanacatib (MK-0822)

Intervention

Odanacatib, Placebo for Odanacatib, Vitamin D3, Calcium carbonate

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.